The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Steven Harr Biography and Net Worth

Pres of Sana Biotechnology

Steve Harr, MD, is President and Chief Executive Officer of Sana Biotechnology.

Prior to co-founding Sana, Steve served as Chief Financial Officer and Head of Corporate Development for Juno Therapeutics until its acquisition by Celgene in early 2018. He was a member of the Board of Directors of Loxo Oncology prior to its acquisition by Eli Lilly in early 2019. Steve also was a co-founder and member of the Board of Directors of JW Therapeutics, a cell therapy company in China. Prior to joining Juno, Steve was at Morgan Stanley, most recently as Managing Director and Head of Biotechnology Investment Banking and previously as a biotech research analyst and co-head of global healthcare research.

Steve obtained a BA in Economics from College of the Holy Cross and an MD from Johns Hopkins University School of Medicine. He was an Internal Medicine resident at the University of California, San Francisco and performed research at Harvard Medical School and Massachusetts General Hospital.

How old is Steven D. Harr?: Dr. Harr is currently 54 years old. There are 7 older executives and no younger executives at Sana Biotechnology. The oldest executive at Sana Biotechnology is Mr. Bernard J. Cassidy J.D., Executive VP, General Counsel & Corporate Secretary, who is 69 years old. Learn More on Steven D. Harr's age.
How do I contact Steven D. Harr?: The corporate mailing address for Dr. Harr and other Sana Biotechnology executives is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. Sana Biotechnology can also be reached via phone at 206-701-7914 and via email at [email protected]. Learn More on Steven D. Harr's contact information.
Has Steven D. Harr been buying or selling shares of Sana Biotechnology?: Steven D. Harr has not been actively trading shares of Sana Biotechnology over the course of the past ninety days. Learn More on Steven D. Harr's trading history.
Who are Sana Biotechnology's active insiders?: Sana Biotechnology's insider roster includes Nathan . (Exec. VP & CFO ), Steven Harr (Pres), and Christian Hordo (EVP). Learn More on Sana Biotechnology's active insiders.
Are insiders buying or selling shares of Sana Biotechnology?: During the last year, Sana Biotechnology insiders bought shares 1 times. They purchased a total of 1,818,181 shares worth more than $9,999,995.50. During the last year, insiders at the sold shares 1 times. They sold a total of 150,000 shares worth more than $612,000.00. The most recent insider tranaction occured on September, 24th when Director Richard Mulligan sold 150,000 shares worth more than $612,000.00. Insiders at Sana Biotechnology own 31.1% of the company. Learn More about insider trades at Sana Biotechnology.
Information on this page was last updated on 9/24/2024.

Steven D. Harr Insider Trading History at Sana Biotechnology

Steven D. Harr Buying and Selling Activity at Sana Biotechnology

Sana Biotechnology Company Overview

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Today's Range

Now: $1.65

$1.55

$1.72

50 Day Range

MA: $2.93

$1.60

$4.23

2 Week Range

Now: $1.65

$1.55

$12.00

Volume

3,201,361 shs

Average Volume

2,143,796 shs

Market Capitalization

$368.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Vladimir Lenin was right…

From Porter & Company | Ad